first-line therapy options for rcc: lessons from checkmate 214 and keynote-427
Published 5 years ago • 110 plays • Length 4:23Download video MP4
Download video MP3
Similar videos
-
5:10
checkmate 214: patterns of progression with nivolumab plus ipilimumab versus sunitinib for rcc
-
1:54
checkmate 214 trial in rcc updates
-
2:30
checkmate 214 trial update
-
2:21
first-line treatment decision making for patients with rcc
-
1:30
targeted therapies for the treatment of mrcc after nivolumab-ipilimumab failure
-
1:28
keynote-b61: first-line lenvatinib pembrolizumab in non-clear cell rcc
-
2:18
pembrolizumab monotherapy and pembro-axitinib for rcc
-
5:58
checkmate 9er update confirms benefits of nivolumab–cabozantinib in rcc | cristina suárez
-
4:50
ipilimumab/nivolumab in first-line mrcc
-
11:58
checkmate 214: nivolumab ipilimumab or sunitinib in patients with advanced renal cell carcinoma
-
2:46
keynote-427 updates: first-line pembrolizumab monotherapy in patients with advanced clear cell r...
-
1:20
renal cell carcinoma: the emulsion and checkmate 214 trials
-
12:48
checkmate 214: 4-year follow-up and subgroup analysis of patients without nephrectomy
-
4:13
checkmate 214: nivolumab ipilimumab vs sunitinib for advanced or metastatic renal cell carcinoma
-
4:20
trial updates in mrcc from asco: keynote-427, resort, e2810 & immotion151
-
39:36
management of first line advanced rcc in era of immuno-oncology
-
0:59
combining lenvatinib & pembrolizumab for non-clear cell rcc: keynote-b61 study rationale
-
4:10
non-clear cell kidney cancer trial updates: calypso and keynote-427
-
9:57
how to select 1st line therapy for metastatic renal cell cancer?